50 related articles for article (PubMed ID: 38508608)
21. Gender Identity Disparities in Cancer Screening Behaviors.
Tabaac AR; Sutter ME; Wall CSJ; Baker KE
Am J Prev Med; 2018 Mar; 54(3):385-393. PubMed ID: 29338956
[TBL] [Abstract][Full Text] [Related]
22. "It Can Promote an Existential Crisis": Factors Influencing Pap Test Acceptability and Utilization Among Transmasculine Individuals.
Peitzmeier SM; Agénor M; Bernstein IM; McDowell M; Alizaga NM; Reisner SL; Pardee DJ; Potter J
Qual Health Res; 2017 Dec; 27(14):2138-2149. PubMed ID: 28836483
[TBL] [Abstract][Full Text] [Related]
23. Pap test use is lower among female-to-male patients than non-transgender women.
Peitzmeier SM; Khullar K; Reisner SL; Potter J
Am J Prev Med; 2014 Dec; 47(6):808-12. PubMed ID: 25455121
[TBL] [Abstract][Full Text] [Related]
24. Female-to-male patients have high prevalence of unsatisfactory Paps compared to non-transgender females: implications for cervical cancer screening.
Peitzmeier SM; Reisner SL; Harigopal P; Potter J
J Gen Intern Med; 2014 May; 29(5):778-84. PubMed ID: 24424775
[TBL] [Abstract][Full Text] [Related]
25. Practice Bulletin No. 140: management of abnormal cervical cancer screening test results and cervical cancer precursors.
American College of Obstetricians and Gynecologists
Obstet Gynecol; 2013 Dec; 122(6):1338-67. PubMed ID: 24264713
[No Abstract] [Full Text] [Related]
26. Endogenous sex steroids and risk of cervical carcinoma: results from the EPIC study.
Rinaldi S; Plummer M; Biessy C; Castellsagué X; Overvad K; Krüger Kjær S; Tjønneland A; Clavel-Chapelon F; Chabbert-Buffet N; Mesrine S; Lukanova A; Kaaks R; Weikert C; Boeing H; Trichopoulou A; Lagiou P; Trichopoulos D; Palli D; Agnoli C; Tumino R; Vineis P; Panico S; Bueno-de-Mesquita B; van Kranen HJ; Peeters PH; Bakken K; Lund E; Gram IT; Rodríguez L; Bosch FX; Sánchez MJ; Dorronsoro M; Navarro C; Gurrea AB; Kjellberg L; Dillner J; Manjer J; Butt S; Khaw KT; Wareham N; Allen NE; Travis R; Romieu I; Ferrari P; Riboli E; Franceschi S
Cancer Epidemiol Biomarkers Prev; 2011 Dec; 20(12):2532-40. PubMed ID: 21994406
[TBL] [Abstract][Full Text] [Related]
27. Papanicolaou smear history in women with low-grade cytology before cervical cancer diagnosis.
Bofin AM; Nygård JF; Skare GB; Dybdahl BM; Westerhagen U; Sauer T
Cancer; 2007 Aug; 111(4):210-6. PubMed ID: 17567833
[TBL] [Abstract][Full Text] [Related]
28. Outcome of women with inadequate cervical smears followed up for five years.
Hock YL; Ramaiah S; Wall ES; Harris AM; Marston L; Marshall J; Kendall K; Teale A
J Clin Pathol; 2003 Aug; 56(8):592-5. PubMed ID: 12890808
[TBL] [Abstract][Full Text] [Related]
29. Advanced-stage cervix cancer: rapid tumour growth rather than late diagnosis.
Symonds P; Bolger B; Hole D; Mao JH; Cooke T
Br J Cancer; 2000 Sep; 83(5):566-8. PubMed ID: 10944592
[TBL] [Abstract][Full Text] [Related]
30. Cervical cancer in a transgender man: lessons learnt to improve care.
Barrison L; Hoskins E
BMJ Case Rep; 2024 Mar; 17(3):. PubMed ID: 38508608
[TBL] [Abstract][Full Text] [Related]
31. Surgical management and gynecologic care of the transgender patient.
Schmidt M; Ditrio L; Shute B; Luciano D
Curr Opin Obstet Gynecol; 2019 Aug; 31(4):228-234. PubMed ID: 31045656
[TBL] [Abstract][Full Text] [Related]
32. A Literature Review of Cervical Cancer Screening in Transgender Men.
Gatos KC
Nurs Womens Health; 2018 Feb; 22(1):52-62. PubMed ID: 29433700
[TBL] [Abstract][Full Text] [Related]
33. Cervical cancer prevention in transgender men: a review.
Weyers S; Garland SM; Cruickshank M; Kyrgiou M; Arbyn M
BJOG; 2021 Apr; 128(5):822-826. PubMed ID: 32931650
[TBL] [Abstract][Full Text] [Related]
34. Bridging Barriers to Cervical Cancer Screening in Transgender Men: A Scoping Review.
Dhillon N; Oliffe JL; Kelly MT; Krist J
Am J Mens Health; 2020; 14(3):1557988320925691. PubMed ID: 32489142
[TBL] [Abstract][Full Text] [Related]
35. Cervical Cancer Screening for Patients on the Female-to-Male Spectrum: a Narrative Review and Guide for Clinicians.
Potter J; Peitzmeier SM; Bernstein I; Reisner SL; Alizaga NM; Agénor M; Pardee DJ
J Gen Intern Med; 2015 Dec; 30(12):1857-64. PubMed ID: 26160483
[TBL] [Abstract][Full Text] [Related]
36. Cytology and LGBT+ health: establishing inclusive cancer screening programs.
Compton ML; Taylor SS; Weeks AG; Weiss VL; Hogan MM; Wang H; Ely KA
J Am Soc Cytopathol; 2022; 11(5):241-252. PubMed ID: 35840516
[TBL] [Abstract][Full Text] [Related]
37. Human Papillomavirus-Related Cancer Surveillance, Prevention, and Screening Among Transgender Men and Women: Neglected Populations at High Risk.
Brown B; Poteat T; Marg L; Galea JT
LGBT Health; 2017 Oct; 4(5):315-319. PubMed ID: 28876211
[TBL] [Abstract][Full Text] [Related]
38. Gender-affirming hormones and surgery in transgender children and adolescents.
Mahfouda S; Moore JK; Siafarikas A; Hewitt T; Ganti U; Lin A; Zepf FD
Lancet Diabetes Endocrinol; 2019 Jun; 7(6):484-498. PubMed ID: 30528161
[TBL] [Abstract][Full Text] [Related]
39. Clinical needs for transgender men in the gynecologic oncology setting.
Stenzel AE; Moysich KB; Ferrando CA; Starbuck KD
Gynecol Oncol; 2020 Dec; 159(3):899-905. PubMed ID: 33004214
[TBL] [Abstract][Full Text] [Related]
40. Routine Screening for Transgender and Gender Diverse Adults Taking Gender-Affirming Hormone Therapy: a Narrative Review.
Iwamoto SJ; Grimstad F; Irwig MS; Rothman MS
J Gen Intern Med; 2021 May; 36(5):1380-1389. PubMed ID: 33547576
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
